Liu S, Edwards D S, Harris A R
The DuPont Merck Pharmaceutical Company, Radiopharmaceuticals Division 331 Treble Cove Road, North Billerica, Massachusetts 01862, USA.
Bioconjug Chem. 1998 Sep-Oct;9(5):583-95. doi: 10.1021/bc9800116.
A hydrazinonicotinamide-functionalized cyclic platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonist [HYNICtide, cyclo(D-Val-NMeArg-Gly-Asp-Mamb(5-(6-(6-hydrazinonicotina mido)hexanamide)))] was labeled with 99mTc using tricine and a series of imine-N-containing heterocycles as coligands. The imine-N-containing heterocycles include N-omega-Acetylhistamine (HIS-AC), N-(2-hydroxyethyl)isonicotinamide (ISONIC-HE), isonicotinic acid (ISONIC), isonicotinoyl-L-aspartic acid dimethyl ester (ISONIC-L-Asp-OMe2), 4-methyl-5-thiazoleethanol (MTE), nicotinic acid (NIC), 3-nitro-1,2,4-triazole (NTZ), 4-pyridylacetic acid (PA), 4-pyridineethanesulfonic acid (PES), and 3-pyridinesulfonic acid (PSA). The synthesis of these new ternary ligand [99mTc]HYNICtide complexes can be performed in one or two steps in high yield and high specific activity (>/=10 000 Ci/mmol HYNICtide). For example, the reaction of HYNICtide, [99mTc]pertechnetate, nicotinic acid, stannous chloride, and tricine at pH approximately 5 and 100 degreesC for 20 min results in the complex [99mTc(HYNICtide)(tricine)(NIC)] in >/=90% yield as determined by radio-HPLC. It was found that ternary ligand technetium complexes, [99mTc(HYNICtide)(tricine)(L)] (L = ISONIC, ISONIC-L-Asp-OMe2, ISONIC-HE, MTE, PA, PES, and PSA) are formed as equal mixtures of two isomeric forms. Complex [99mTc(HYNICtide)(tricine)(L)] (L = HIS-AC and NTZ) showed more than two well-resolved radiometric peaks at the retention times of interest, suggesting that they may have more than two forms in solution due to different bonding modalities of HIS-AC and NTZ. By a chirality experiment, it was found that the presence of two radiometric peaks is a result of the resolution of the two diastereomers which are formed by the combination of the chiral HYNICtide and the chiral technetium chelate. The formation of two diastereomers was also observed when a chiral imine-N-containing coligand was used for the radiolabeling of HYNIC-BA. The new ternary ligand [99mTc]HYNICtide complexes were found to be stable for up to 6 h in the reaction mixture. The high solution stability is attributed to their kinetic inertness. The composition of these complexes was determined to be 1:1:1:1 for Tc:HYNICtide:L:tricine (L = imine-N-containing heterocycles) through a series of mixed ligand experiments on the tracer (99mTc) level. The lipophilicity of the ternary ligand [99mTc]HYNICtide complexes can be systematically varied by the choice of polyaminocarboxylate and imine-N-containing coligands. Using the combination of tricine and an imine-N-containing coligand, HYNIC-derivatized peptides or other small molecules can be labeled with 99mTc in high specific activity and high stability for potential use as radiopharmaceuticals.
一种肼基烟酰胺功能化的环状血小板糖蛋白IIb/IIIa(GPIIb/IIIa)受体拮抗剂[HYNICtide,环(D-缬氨酸-N-甲基精氨酸-甘氨酸-天冬氨酸-Mamb(5-(6-(6-肼基烟酰胺基)己酰胺)))],使用三羟甲基氨基甲烷(tricine)和一系列含亚胺氮的杂环作为共配体,用99mTc进行标记。含亚胺氮的杂环包括N-ω-乙酰组胺(HIS-AC)、N-(2-羟乙基)异烟酰胺(ISONIC-HE)、异烟酸(ISONIC)、异烟酰-L-天冬氨酸二甲酯(ISONIC-L-Asp-OMe2)、4-甲基-5-噻唑乙醇(MTE)、烟酸(NIC)、3-硝基-1,2,4-三唑(NTZ)、4-吡啶乙酸(PA)、4-吡啶乙烷磺酸(PES)和3-吡啶磺酸(PSA)。这些新型三元配体[99mTc]HYNICtide配合物的合成可以通过一步或两步高产率、高比活(≥10 000 Ci/mmol HYNICtide)进行。例如,HYNICtide、高锝[99mTc]酸盐、烟酸、氯化亚锡和三羟甲基氨基甲烷在pH约为5和100℃下反应20分钟,通过放射性高效液相色谱法测定,产物[99mTc(HYNICtide)(tricine)(NIC)]的产率≥90%。研究发现,三元配体锝配合物[99mTc(HYNICtide)(tricine)(L)](L = ISONIC、ISONIC-L-Asp-OMe2、ISONIC-HE、MTE、PA、PES和PSA)以两种异构体形式的等量混合物形成。配合物[99mTc(HYNICtide)(tricine)(L)](L = HIS-AC和NTZ)在感兴趣的保留时间处显示出两个以上分辨良好的放射性峰,这表明由于HIS-AC和NTZ的不同键合方式,它们在溶液中可能有两种以上的形式。通过手性实验发现,两个放射性峰的存在是由手性HYNICtide和手性锝螯合物结合形成的两个非对映异构体拆分的结果。当使用手性含亚胺氮的共配体对HYNIC-BA进行放射性标记时,也观察到了两种非对映异构体的形成。发现新型三元配体[99mTc]HYNICtide配合物在反应混合物中长达6小时都是稳定的。高溶液稳定性归因于它们的动力学惰性。通过在示踪剂(99mTc)水平上进行一系列混合配体实验,确定这些配合物的组成对于Tc:HYNICtide:L:tricine(L = 含亚胺氮的杂环)为1:1:1:1。通过选择多氨基羧酸盐和含亚胺氮的共配体,可以系统地改变三元配体[99mTc]HYNICtide配合物的亲脂性。使用三羟甲基氨基甲烷和含亚胺氮的共配体的组合,HYNIC衍生的肽或其他小分子可以用99mTc进行高比活和高稳定性的标记,有潜力用作放射性药物。